Literature DB >> 7513854

Significance of supraventricular tachyarrhythmias in patients with implanted pacing cardioverter defibrillators.

C Schmitt1, M Montero, J Melichercik.   

Abstract

Eighty-six patients were treated with an implantable cardioverter defibrillator (ICD) because of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF). In 27 patients an epicardial system was used, in 59 patients a transvenous system with a subcutaneous patch electrode was implanted. During a mean follow-up time of 17 +/- 9 months, inappropriate activations of the ICD due to supraventricular tachycardia were documented by Holter monitoring in 14 patients (16%). In 8 patients paroxysmal atrial fibrillation (AF), in 2 patients chronic AF, in 1 patient atrial flutter, and in 3 patients sinus tachycardia triggered antitachycardia pacing functions (12 patients) or internal defibrillation (2 patients). In 3 patients (5%) VT was induced by inappropriate antitachycardia pacing. In an additional 18 patients (21%) inappropriate activation of antitachycardia functions due to atrial tachyarrhythmias were suspected based on telemetry readouts or the patient's history. Inappropriate activation of ICD therapy triggered by intermittent supraventricular tachyarrhythmias is common. Further improvements of detection algorithms for supraventricular tachycardia are required in future device generations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513854     DOI: 10.1111/j.1540-8159.1994.tb01391.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  9 in total

Review 1.  Implantable dual-chamber cardioverter-defibrillator-pacemaker.

Authors:  D Pfeiffer; M Mende; A Hagendorff
Journal:  Curr Cardiol Rep       Date:  2000-07       Impact factor: 2.931

2.  Multicenter automatic defibrillator implantation trial: reduce inappropriate therapy (MADIT-RIT): background, rationale, and clinical protocol.

Authors:  Claudio Schuger; James P Daubert; Mary W Brown; David Cannom; N A Mark Estes; W Jackson Hall; Torsten Kayser; Helmut Klein; Brian Olshansky; Keith A Power; David Wilber; Wojciech Zareba; Arthur J Moss
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-07       Impact factor: 1.468

3.  Implantable defibrillators configured for hybrid therapy of persistent and permanent atrial fibrillation: initial clinical experience with a novel lead system.

Authors:  Hygriv B Rao; Sanjeev Saksena
Journal:  J Interv Card Electrophysiol       Date:  2005-08       Impact factor: 1.900

Review 4.  The role of remote monitoring in the reduction of inappropriate implantable cardioverter defibrillator therapies.

Authors:  J C J Res; D A M J Theuns; L Jordaens
Journal:  Clin Res Cardiol       Date:  2006       Impact factor: 5.460

5.  Comparison of therapy detection times between implantable cardioverter defibrillators with standard dual- and single-chamber pacing.

Authors:  A Capucci; G Q Villani; F Groppi; D Aschieri; M Hull; M Kuehl
Journal:  J Interv Card Electrophysiol       Date:  1999-12       Impact factor: 1.900

6.  Treatment of atrial fibrillation with a dual defibrillator in heart failure patients (TRADE HF): protocol for a randomized clinical trial.

Authors:  Giovanni Luca Botto; Giuseppe Boriani; Stefano Favale; Maurizio Landolina; Giulio Molon; Claudio Tondo; Mauro Biffi; Giuseppe Grandinetti; Paolo De Filippo; Giovanni Raciti; Luigi Padeletti
Journal:  Trials       Date:  2011-02-15       Impact factor: 2.279

7.  Selecting dual chamber or single chamber implantable defibrillators: what is the golden rule?

Authors:  Massimo Santini; Renato Ricci
Journal:  Indian Pacing Electrophysiol J       Date:  2003-10-01

8.  Atrial fibrillation and pacing algorithms.

Authors:  Paolo Terranova; Barbara Severgnini; Paolo Valli; Simonetta Dell'Orto; Enrico Maria Greco
Journal:  Indian Pacing Electrophysiol J       Date:  2006-07-01

Review 9.  Inappropriate shocks in patients with ICDs: single chamber versus dual chamber.

Authors:  Juliana Gonçalves; Telmo Pereira
Journal:  Arq Bras Cardiol       Date:  2013-07-02       Impact factor: 2.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.